Prognostic significance of axillary dissection in breast cancer patients with micrometastases or isolated tumor cells in sentinel nodes: a nationwide study

Breast Cancer Research and Treatment
T F TvedskovNiels Kroman

Abstract

We estimated the impact of axillary lymph node dissection (ALND) on the risk of axillary recurrence (AR) and overall survival (OS) in breast cancer patients with micrometastases or isolated tumor cells (ITC) in sentinel nodes. We used the Danish Breast Cancer Cooperative Group (DBCG) database to identify patients with micrometastases or ITC in sentinel nodes following surgery for primary breast cancer between 2002 and 2008. A Cox proportional hazard regression model was developed to assess the hazard ratios (HR) for AR and OS between patients with and without ALND. We identified 2074 patients, of which 240 did not undergo further axillary surgery. The 5-year cumulated incidence for AR was 1.58 %. No significant difference in AR was seen between patients with and without ALND. The age adjusted HR for AR if ALND was omitted was 1.79 (95 % CI 0.41-7.80, P = 0.44) in patients with micrometastases and 2.21 (95 % CI 0.54-8.95, P = 0.27), in patients with ITC after a median follow-up of 6 years and 3 months. There was no significant difference in overall survival between patients with and without ALND, when adjusting for age, co-morbidity, tumor size, histology type, malignancy grade, lymphovascular invasion, hormone receptor status, ...Continue Reading

References

Aug 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S Eva SingletaryFrederick L Greene
Aug 5, 2005·Annals of Surgical Oncology·Yang-Guo FanStanley P L Leong
Jan 29, 2008·Journal of the American College of Surgeons·Charles E CoxDavid Boulware
May 10, 2008·Acta Oncologica·Peer ChristiansenUNKNOWN Danish Breast Cancer Cooperative Group
Nov 13, 2008·Journal of the National Cancer Institute·Carolien H M van DeurzenPaul J van Diest
Apr 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Karl Y BilimoriaDavid J Winchester
Aug 14, 2009·The New England Journal of Medicine·Maaike de BoerVivianne C G Tjan-Heijnen
Oct 26, 2010·Breast Cancer Research and Treatment·Manon J PepelsVivianne C G Tjan-Heijnen
Nov 20, 2010·European Surgical Research. Europäische Chirurgische Forschung. Recherches Chirurgicales Européennes·T OnishiY Kitagawa
Dec 1, 2010·Asia-Pacific Journal of Clinical Oncology·Stephen M KiharaPaul Crea
Jan 5, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Tove Filtenborg TvedskovNiels Kroman
Feb 10, 2011·JAMA : the Journal of the American Medical Association·Armando E GiulianoMonica Morrow
Apr 7, 2011·Breast Cancer Research and Treatment·Viviana GalimbertiUmberto Veronesi
Jun 3, 2011·Breast Care·Michael GnantChristoph Thomssen
Jul 27, 2011·Surgical Oncology·Mohamed SalhabKefah Mokbel
Dec 21, 2011·Annals of Surgery·Manon J PepelsVivianne C G Tjan-Heijnen
Aug 15, 2012·Annals of Surgical Oncology·Claire M T P FrancissenJohannes H W de Wilt
Mar 16, 2013·The Lancet Oncology·Viviana GalimbertiUNKNOWN International Breast Cancer Study Group Trial 23-01 investigators

❮ Previous
Next ❯

Citations

Jan 13, 2016·Journal of Pathology and Translational Medicine·Sophia K Apple
Apr 2, 2017·Annals of Surgical Oncology·Liling ZhuRebecca Aft
Aug 30, 2018·NPJ Breast Cancer·Kim R M BlenmanPeter P Lee
Feb 6, 2020·Critical Reviews in Oncology/hematology·Angel MonteroCarmen Rubio

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.